BAUDAX BIO INC (BXRX)
US07160F4046 - Common Stock
Taking everything into account, BXRX scores 1 out of 10 in our fundamental rating. BXRX was compared to 191 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of BXRX have multiple concerns. BXRX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BXRX has reported negative net income.
In the past year BXRX has reported a negative cash flow from operations.
BXRX had negative earnings in each of the past 5 years.
In the past 5 years BXRX always reported negative operating cash flow.
1.2 Ratios
BXRX has a worse Return On Assets (-161.54%) than 88.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.54% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-246.2%
ROA(5y)-201.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for BXRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
BXRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BXRX has been increased compared to 1 year ago.
BXRX has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -17.15, we must say that BXRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of BXRX (-17.15) is worse than 86.41% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -17.15 |
ROIC/WACCN/A
WACC6.12%
2.3 Liquidity
BXRX has a Current Ratio of 0.09. This is a bad value and indicates that BXRX is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of BXRX (0.09) is worse than 99.03% of its industry peers.
BXRX has a Quick Ratio of 0.09. This is a bad value and indicates that BXRX is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.09, BXRX is not doing good in the industry: 99.03% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.09 | ||
| Quick Ratio | 0.09 |
3. Growth
3.1 Past
BXRX shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 7.23%.
Looking at the last year, BXRX shows a very negative growth in Revenue. The Revenue has decreased by -19.12% in the last year.
EPS 1Y (TTM)7.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.38%
Revenue 1Y (TTM)-19.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, BXRX will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.89% on average per year.
The Revenue is expected to grow by 149.06% on average over the next years. This is a very strong growth
EPS Next Y99.19%
EPS Next 2Y41.36%
EPS Next 3Y25.96%
EPS Next 5Y14.89%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y149.06%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for BXRX. In the last year negative earnings were reported.
Also next year BXRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
BXRX's earnings are expected to grow with 25.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.36%
EPS Next 3Y25.96%
5. Dividend
5.1 Amount
BXRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
BAUDAX BIO INC
NASDAQ:BXRX (11/15/2023, 8:21:44 PM)
After market: 0.17 -0.02 (-8.8%)0.1864
+0 (+0.59%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners0%
Inst Owner Change0%
Ins Owners8.97%
Ins Owner Change0%
Market Cap1.71M
Analysts43.33
Price Target24.48 (13033.05%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-69.86%
Min EPS beat(2)-166.67%
Max EPS beat(2)26.95%
EPS beat(4)1
Avg EPS beat(4)-46.41%
Min EPS beat(4)-166.67%
Max EPS beat(4)26.95%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)42.39%
EPS NY rev (1m)0%
EPS NY rev (3m)-71.87%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.11 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-44.16
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-1.72
FCFYN/A
OCF(TTM)-1.72
OCFYN/A
SpS0.06
BVpS-0.18
TBVpS-1.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -161.54% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-246.2%
ROA(5y)-201.81%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.09 | ||
| Quick Ratio | 0.09 | ||
| Altman-Z | -17.15 |
F-Score3
WACC6.12%
ROIC/WACCN/A
Cap/Depr(3y)11%
Cap/Depr(5y)240.77%
Cap/Sales(3y)50.24%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%96.38%
EPS Next Y99.19%
EPS Next 2Y41.36%
EPS Next 3Y25.96%
EPS Next 5Y14.89%
Revenue 1Y (TTM)-19.12%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y149.06%
EBIT growth 1Y-1230.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y69.15%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.75%
OCF growth 3YN/A
OCF growth 5YN/A